FDA accepts ARS Pharma's NDA for Neffy

ARS Pharmaceuticals has pleased its acquirer with the news that the US regulator will review its lead drug candidate.

The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Neffy (epinephrine nasal spray), an emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs), filed by ARS Pharma, which Silverback Therapeutics (Nasdaq: SBTX) is in the process of acquiring

In July this year, Silverback and privately-held ARS Pharma announced they had entered into a definitive agreement under which the companies are merging in an all-stock transaction, which has not yet completed.